Home > > > > > Report Detail

Gastrointestinal Diseases Drug Development Pipeline Review, 2018

Publisher Name :
Date: 20-Dec-2018
No. of pages: 98

Summary

This report provides an overview of the pipeline landscape for gastrointestinal diseases. It provides comprehensive information on the therapeutics under development and key players involved in therapeutic development for gastroenteritis, enterocolitis, gastritis and peritonitis, and features dormant and discontinued products.

Gastroenteritis is an infection of the gut. Symptoms include stomach pain, cramping, fever, nausea, and a headache. Causes of gastroenteritis include contaminated food or water and contact with someone who has the virus. Treatment includes antibiotics, anti-emetic and anti-diarrheal medications. There are 12 products in development for this indication.

Enterocolitis is an inflammation of the large and small intestines. Symptoms include fever, abdominal swelling, nausea, diarrhea, rectal bleeding and sluggishness. Causes of enterocolitis include inflammation of the intestinal tissues, delayed gastric emptying, abdominal wall erythema, apnea, sepsis and cardiovascular collapse. Treatment includes antibiotics. There are eight products in development for this indication.

Gastritis is characterized by inflammation or swelling of the lining of the stomach. Acute gastritis lasts for a short period of time while chronic gastritis lasts for a long period of time (months to years). Gastritis can be caused by medications such as ibuprofen, aspirin, naproxen on long periods of consumption, excess intake of alcohol, Helicobacter pylori infection, certain autoimmune disorders, bile reflux, substance abuse (cocaine), consumption of corrosive or caustic substances such as poisons, extreme stress, viral infections and trauma. The symptoms of gastritis may include loss of appetite, nausea and vomiting, abdominal pain and black stools. Treatment includes use of antacids, histamine 2 (H2) antagonists and proton pump inhibitors. There are 11 products in development for this indication.

Peritonitis is inflammation of the peritoneum. There are two types of peritonitis. Spontaneous bacterial peritonitis is the result of an infection of the fluid in the peritoneal cavity. Secondary peritonitis is usually due to an infection that has spread from the digestive tract. Symptoms include abdominal bloating, nausea and vomiting, diarrhea, fatigue, fever and chills. Treatment includes antibiotics. There are seven products in development for this indication.

Molecular targets in development for gastrointestinal diseases include toll-like receptors, interleukin receptors and bacterial proteins. Companies operating in this pipeline space include Kyowa Hakko Kirin, RedHill Biopharma and GlaxoSmithKline.

Scope


  • Which companies are the most active within each pipeline?

  • Which pharmaceutical approaches are the most prominent at each stage of the pipeline and within each indication?

  • To what extent do universities and institutions play a role within this pipeline, compared to pharmaceutical companies?

  • What are the most important R&D milestones and data publications to have happened in this disease area?


Reasons to buy


  • Understand the overall pipeline, with an at-a-glance overview of all products in therapeutic development for each indication

  • Assess the products in development in granular detail, with an up-to-date overview of each individual pipeline program in each indication and a comprehensive picture of recent updates and milestones for each

  • Analyze the companies, institutions and universities currently operating in the pipeline and the products being fielded by each of these

  • Understand the composition of the pipeline in terms of molecule type, molecular target, mechanism of action and route of administration

Gastrointestinal Diseases Drug Development Pipeline Review, 2018

Table of Contents

1 Table of Contents 4
1.1 List of Tables 5
1.2 List of Figures 5

2 Introduction 6
2.1 Gastrointestinal Diseases Report Coverage 6
2.2 Gastroenteritis - Overview 6
2.3 Enterocolitis - Overview 6
2.4 Gastritis - Overview 6
2.5 Peritonitis - Overview 6

3 Therapeutics Development 7
3.1 Gastroenteritis 7
3.2 Enterocolitis 11
3.3 Gastritis 14
3.4 Peritonitis 17

4 Therapeutics Assessment 20
4.1 Gastroenteritis 20
4.2 Enterocolitis 26
4.3 Gastritis 31
4.4 Peritonitis 37

5 Companies Involved in Therapeutics Development 44
5.1 Gastroenteritis 44
5.2 Enterocolitis 49
5.3 Gastritis 51
5.4 Peritonitis 55

6 Dormant Projects 58
6.1 Gastroenteritis 58
6.2 Enterocolitis 58
6.3 Gastritis 59
6.4 Peritonitis 60

7 Discontinued Products 61
7.1 Gastroenteritis 61

8 Product Development Milestones 62
8.1 Gastroenteritis 62
8.2 Enterocolitis 78
8.3 Gastritis 87
8.4 Peritonitis 94

9 Appendix 96
9.1 Methodology 96
9.2 Coverage 96
9.3 Secondary Research 96
9.4 Primary Research 96
9.5 Expert Panel Validation 96
9.6 Contact Us 96
9.7 Disclaimer 97

List of Tables

Table 1: Number of Products under Development for Gastroenteritis 8
Table 2: Number of Products under Development by Companies, Gastroenteritis 9
Table 3: Number of Products under Development by Universities/Institutes, Gastroenteritis 10
Table 4: Products under Development by Companies, Gastroenteritis 11
Table 5: Products under Development by Universities/Institutes, Gastroenteritis 11
Table 6: Number of Products under Development for Enterocolitis 12
Table 7: Number of Products under Development by Companies, Enterocolitis 13
Table 8: Number of Products under Development by Universities/Institutes, Enterocolitis 14
Table 9: Products under Development by Companies, Enterocolitis 14
Table 10: Products under Development by Universities/Institutes, Enterocolitis 14
Table 11: Number of Products under Development for Gastritis 15
Table 12: Number of Products under Development by Companies, Gastritis 16
Table 13: Products under Development by Companies, Gastritis 17
Table 14: Number of Products under Development for Peritonitis 18
Table 15: Number of Products under Development by Companies, Peritonitis 19
Table 16: Products under Development by Companies, Peritonitis 20
Table 17: Number of Products by Stage and Target, Gastroenteritis 22
Table 18: Number of Products by Stage and Mechanism of Action, Gastroenteritis 23
Table 19: Number of Products by Stage and Route of Administration, Gastroenteritis 25
Table 20: Number of Products by Stage and Molecule Type, Gastroenteritis 26
Table 21: Number of Products by Stage and Target, Enterocolitis 28
Table 22: Number of Products by Stage and Mechanism of Action, Enterocolitis 29
Table 23: Number of Products by Stage and Route of Administration, Enterocolitis 30
Table 24: Number of Products by Stage and Molecule Type, Enterocolitis 32
Table 25: Number of Products by Stage and Target, Gastritis 33
Table 26: Number of Products by Stage and Mechanism of Action, Gastritis 35
Table 27: Number of Products by Stage and Route of Administration, Gastritis 36
Table 28: Number of Products by Stage and Molecule Type, Gastritis 38
Table 29: Number of Products by Stage and Target, Peritonitis 39
Table 30: Number of Products by Stage and Mechanism of Action, Peritonitis 41
Table 31: Number of Products by Stage and Route of Administration, Peritonitis 42
Table 32: Number of Products by Stage and Molecule Type, Peritonitis 44
Table 33: Gastroenteritis - Pipeline by Kyowa Hakko Kirin Co Ltd 45
Table 34: Gastroenteritis - Pipeline by Medicago Inc 46
Table 35: Gastroenteritis - Pipeline by Ology Bioservices Inc 46
Table 36: Gastroenteritis - Pipeline by RedHill Biopharma Ltd 47
Table 37: Gastroenteritis - Pipeline by Regeneron Pharmaceuticals Inc 47
Table 38: Gastroenteritis - Pipeline by Takeda Pharmaceutical Co Ltd 48
Table 39: Gastroenteritis - Pipeline by UMN Pharma Inc 49
Table 40: Gastroenteritis - Pipeline by Vaxart Inc 49
Table 41: Enterocolitis - Pipeline by Avexegen Therapeutics Inc 50
Table 42: Enterocolitis - Pipeline by Infant Bacterial Therapeutics AB 50
Table 43: Enterocolitis - Pipeline by Leadiant Biosciences Inc 51
Table 44: Enterocolitis - Pipeline by ProMetic Life Sciences Inc 51
Table 45: Gastritis - Pipeline by BCWorld Pharm Co Ltd 52
Table 46: Gastritis - Pipeline by Daewon Pharm Co Ltd 53
Table 47: Gastritis - Pipeline by Daewoong Pharmaceutical Co Ltd 53
Table 48: Gastritis - Pipeline by Kyowa Hakko Kirin Co Ltd 54
Table 49: Gastritis - Pipeline by Recce Ltd 55
Table 50: Gastritis - Pipeline by RedHill Biopharma Ltd 55
Table 51: Gastritis - Pipeline by Sequella Inc 56
Table 52: Peritonitis - Pipeline by GlaxoSmithKline Plc 56
Table 53: Peritonitis - Pipeline by Nosopharm SAS 57
Table 54: Peritonitis - Pipeline by Oncodesign SA 57
Table 55: Peritonitis - Pipeline by SynAct Pharma AB 58
Table 56: Gastroenteritis - Dormant Projects 59
Table 57: Enterocolitis - Dormant Projects 59
Table 58: Gastritis - Dormant Projects 60
Table 59: Peritonitis - Dormant Projects 61
Table 60: Gastroenteritis - Discontinued Products 62

List of Figures

Figure 1: Number of Products under Development for Gastroenteritis 8
Figure 2: Number of Products under Development by Companies, Gastroenteritis 9
Figure 3: Number of Products under Development by Universities/Institutes, Gastroenteritis 10
Figure 4: Number of Products under Development for Enterocolitis 12
Figure 5: Number of Products under Development by Companies, Enterocolitis 13
Figure 6: Number of Products under Development for Gastritis 15
Figure 7: Number of Products under Development by Companies, Gastritis 16
Figure 8: Number of Products under Development for Peritonitis 18
Figure 9: Number of Products under Development by Companies, Peritonitis 19
Figure 10: Number of Products by Targets, Gastroenteritis 21
Figure 11: Number of Products by Stage and Targets, Gastroenteritis 21
Figure 12: Number of Products by Mechanism of Actions, Gastroenteritis 22
Figure 13: Number of Products by Stage and Mechanism of Actions, Gastroenteritis 23
Figure 14: Number of Products by Routes of Administration, Gastroenteritis 24
Figure 15: Number of Products by Stage and Routes of Administration, Gastroenteritis 24
Figure 16: Number of Products by Molecule Types, Gastroenteritis 25
Figure 17: Number of Products by Stage and Molecule Types, Gastroenteritis 26
Figure 18: Number of Products by Targets, Enterocolitis 27
Figure 19: Number of Products by Stage and Targets, Enterocolitis 27
Figure 20: Number of Products by Mechanism of Actions, Enterocolitis 28
Figure 21: Number of Products by Stage and Mechanism of Actions, Enterocolitis 29
Figure 22: Number of Products by Stage and Routes of Administration, Enterocolitis 30
Figure 23: Number of Products by Molecule Types, Enterocolitis 31
Figure 24: Number of Products by Stage and Molecule Types, Enterocolitis 31
Figure 25: Number of Products by Targets, Gastritis 32
Figure 26: Number of Products by Stage and Targets, Gastritis 33
Figure 27: Number of Products by Mechanism of Actions, Gastritis 34
Figure 28: Number of Products by Stage and Mechanism of Actions, Gastritis 34
Figure 29: Number of Products by Routes of Administration, Gastritis 35
Figure 30: Number of Products by Stage and Routes of Administration, Gastritis 36
Figure 31: Number of Products by Molecule Types, Gastritis 37
Figure 32: Number of Products by Stage and Molecule Types, Gastritis 37
Figure 33: Number of Products by Targets, Peritonitis 38
Figure 34: Number of Products by Stage and Targets, Peritonitis 39
Figure 35: Number of Products by Mechanism of Actions, Peritonitis 40
Figure 36: Number of Products by Stage and Mechanism of Actions, Peritonitis 40
Figure 37: Number of Products by Routes of Administration, Peritonitis 41
Figure 38: Number of Products by Stage and Routes of Administration, Peritonitis 42
Figure 39: Number of Products by Molecule Types, Peritonitis 43
Figure 40: Number of Products by Stage and Molecule Types, Peritonitis 43

  • Global Anti-Peptic Ulcer Drugs Market Growth (Status and Outlook) 2024-2030
    Published: 04-Jan-2024        Price: US 3660 Onwards        Pages: 110
    According to our LPI (LP Information) latest study, the global Anti-Peptic Ulcer Drugs market size was valued at US$ 8523.5 million in 2023. With growing demand in downstream market, the Anti-Peptic Ulcer Drugs is forecast to a readjusted size of US$ 21200 million by 2030 with a CAGR of 13.9% during review period. The research report highlights the growth potential of the global Anti-Peptic Ulcer Drugs market. Anti-Peptic Ulcer Drugs are expected to show stable growth in the future marke......
  • Global Lansoprazole Market Research Report 2024
    Published: 04-Jan-2024        Price: US 2900 Onwards        Pages: 102
    The Lansoprazole market size, estimations, and forecasts are provided in terms of sales volume (K Units) and revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global Lansoprazole market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided. For a more in-depth understanding of the market, the report provides profiles of the comp......
  • Global Irritable Bowel Syndrome (IBS) Market Growth (Status and Outlook) 2024-2030
    Published: 04-Jan-2024        Price: US 3660 Onwards        Pages: 88
    According to our LPI (LP Information) latest study, the global Irritable Bowel Syndrome (IBS) market size was valued at US$ 4634.2 million in 2023. With growing demand in downstream market, the Irritable Bowel Syndrome (IBS) is forecast to a readjusted size of US$ 12750 million by 2030 with a CAGR of 15.6% during review period. The research report highlights the growth potential of the global Irritable Bowel Syndrome (IBS) market. Irritable Bowel Syndrome (IBS) are expected to show stabl......
  • Global Esomeprazole Market Research Report 2024
    Published: 04-Jan-2024        Price: US 2900 Onwards        Pages: 89
    The Esomeprazole market size, estimations, and forecasts are provided in terms of sales volume (K Units) and revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global Esomeprazole market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided. For a more in-depth understanding of the market, the report provides profiles of the comp......
  • Global Irritable Bowel Syndrome (IBS) Industry Research Report, In-depth Analysis of Current Status and Outlook of Key Countries 2023-2028
    Published: 02-Jan-2024        Price: US 3380 Onwards        Pages: 126
    Market Overview of Global Irritable Bowel Syndrome (IBS) market: According to our latest research, the global Irritable Bowel Syndrome (IBS) market looks promising in the next 5 years. As of 2022, the global Irritable Bowel Syndrome (IBS) market was estimated at USD XX million, and it's anticipated to reach USD XX million in 2028, with a CAGR of XX% during the forecast years. This report covers a research time span from 2018 to 2028, and presents a deep and comprehensive anal......
  • Global Diarrhea Drug Industry Research Report, In-depth Analysis of Current Status and Outlook of Key Countries 2023-2028
    Published: 28-Dec-2023        Price: US 3380 Onwards        Pages: 109
    Market Overview of Global Diarrhea Drug market: According to our latest research, the global Diarrhea Drug market looks promising in the next 5 years. As of 2022, the global Diarrhea Drug market was estimated at USD XX million, and it's anticipated to reach USD XX million in 2028, with a CAGR of XX% during the forecast years. This report covers a research time span from 2018 to 2028, and presents a deep and comprehensive analysis of the global Diarrhea Drug market, with a sys......
  • Drugs for Traveler's Diarrhea - Global Market Insights and Sales Trends 2024
    Published: 27-Dec-2023        Price: US 3350 Onwards        Pages: 96
    This report provides market insight on the different segments, by manufacturers, by Type, by Application. Market size and forecast (2018-2029) has been provided in the report. The primary objectives of this report are to provide 1) global market size and forecasts, growth rates, market dynamics, industry structure and developments, market situation, trends; 2) global market share and ranking By Company; 3) comprehensive presentation of the global market for Drugs for Traveler's Diarrhea, with bo......
  • Global Lansoprazole Professional Survey Report 2023, Forecast to 2028
    Published: 26-Dec-2023        Price: US 3280 Onwards        Pages: 136
    Lansoprazole reduces the amount of acid your stomach makes. It's used for indigestion, heartburn and acid reflux and gastroesophageal-reflux-disease (GORD). Lansoprazole is also taken to prevent and treat stomach ulcers. Our market research experts provide qualitative and quantitative analysis of the market based on involving economic and non-economic factors in the same report with market value (million USD) data for each segment and sub-segment. This way, clients can achieve all their g......
  • Global Pentasa (Ulcerative Colitis) Industry Research Report, In-depth Analysis of Current Status and Outlook of Key Countries 2023-2028
    Published: 26-Dec-2023        Price: US 3380 Onwards        Pages: 113
    Market Overview of Global Pentasa (Ulcerative Colitis) market: According to our latest research, the global Pentasa (Ulcerative Colitis) market looks promising in the next 5 years. As of 2022, the global Pentasa (Ulcerative Colitis) market was estimated at USD XX million, and it's anticipated to reach USD XX million in 2028, with a CAGR of XX% during the forecast years. This report covers a research time span from 2018 to 2028, and presents a deep and comprehensive analysis o......
    • SERVICES
    Value for Money
    We believe in "optimum utilization of available budget and resources". While servicing our clients' (your) market research requirements, we keep the same approach in focus to help you get the best value for your $$s.
    Ever Growing Inventory
    Ranging from the smallest feasible / required data (datasheets, data facts, SWOT analysis, company profiles, etc) to full research reports that help you make decisions, our inventory is updated almost on a daily basis with the latest industry reports from domain experts that track more than 5000 niche sectors.
    One Stop Solution
    Need a custom research report on medical devices market? Require all available business intelligence on 3D printing industry? Exploring F&B sector of a particular country/region? RnRMarketResearch.com is your one-stop-solution to all market intelligence needs. We not only offer custom research and consulting services, we also "bundle" reports to meet your needs and help you fetch the data analysis you require for your business.
    Dedicated Client Engagement
    Not limited to only "finding" relevant reports for you, our client engagement team dedicates its efforts to understand your "business need" and accordingly maps available research data to help you move forward. Call "your" client engagement executive any time of your day and get your questions answered in order to make the correct business decision.
    Saving Time and Efforts
    Simply share your research requirement details with us and let us do all the hard work to find required intelligence for you. When you add up our "one stop solution" and "dedicated client engagement" services mentioned above, you obviously know the time and effort saving you do by working with us.
    Payment Flexibility
    Working with Fortune 500 organizations, we understand the importance of being flexible for payments. Share your payment terms with us and we will surely match up to them to ensure you get access to required business intelligence data without having to wait for the payment to be done.
    Post-Purchase Research Support
    Have questions after reading a report / datasheet bought through us? Not sure about the methodology used for data available in the research? Talk to us / Share your questions with us and if required, we will connect you with the analyst(s)/author(s) of the report(s) and ensure you get satisfactory answers for the same. Need more data / analysis / report(s) on the topic of your research/project? The RnRMarketResearch.com team is here for you 24X7 to support you with your post-purchase requirements. Subscription Offers & Packages (Get in touch with us for more details - [email protected] / +1 888 391 5441 )
    • Ad Hoc
    • Pay - as - you - go / Bucket Subscriptions
    • Fixed Cost for #of reports
    • Customize / Personalize as per your needs